Toru Mitsumori

Urayasu, 2790021, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

A New Histology-Based Prognostic Index for Acute Lymphoblastic Leukemia: Preliminary Results of the "ALL Urayasu Classification".

A New Histology-Based Prognostic Index for Acute Lymphoblastic Leukemia: Preliminary Results of the "ALL Urayasu Classification".

Journal: Journal of clinical medicine

Published: November 24, 2025

Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.

Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.

Journal: International journal of hematology

Published: September 03, 2025

The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Journal: Cardio-oncology (London, England)

Published: February 13, 2025

A New Histology-Based Prognostic Index for Acute Myeloid Leukemia: Preliminary Results for the "AML Urayasu Classification".

A New Histology-Based Prognostic Index for Acute Myeloid Leukemia: Preliminary Results for the "AML Urayasu Classification".

Journal: Journal of clinical medicine

Published: January 14, 2025

Eleven cases of laryngeal edema after tisagenlecleucel infusion: a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas.

Eleven cases of laryngeal edema after tisagenlecleucel infusion: a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas.

Journal: Haematologica

Published: July 11, 2024

A New Histology-Based Prognostic Index for Aggressive T-Cell lymphoma: Preliminary Results of the "TCL Urayasu Classification".

A New Histology-Based Prognostic Index for Aggressive T-Cell lymphoma: Preliminary Results of the "TCL Urayasu Classification".

Journal: Journal of clinical medicine

Published: April 10, 2024

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.

Journal: International journal of hematology

Published: October 19, 2023

Possible New Histological Prognostic Index for Large B-Cell Lymphoma.

Possible New Histological Prognostic Index for Large B-Cell Lymphoma.

Journal: Journal of clinical medicine

Published: August 16, 2023

Role of TGF-beta1 and TNF-alpha1 produced by neoplastic cells in the pathogenesis of fibrosis in patients with hematologic neoplasms.

Role of TGF-beta1 and TNF-alpha1 produced by neoplastic cells in the pathogenesis of fibrosis in patients with hematologic neoplasms.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: April 30, 2023

Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.

Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.

Journal: Internal medicine (Tokyo, Japan)

Published: April 02, 2023

Development of rapidly fatal TAFRO syndrome-like features in a patient with essential thrombocythemia.

Development of rapidly fatal TAFRO syndrome-like features in a patient with essential thrombocythemia.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: March 29, 2023

Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.

Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.

Journal: International journal of hematology

Published: February 03, 2023

Showing 1-12 of 38

Last Updated: 09/26/2026